Double Immunosuppression With or Without Anti-fibrotic in Scleroderma ILD
ConditionSSc-Systemic Sclerosis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Patras
About this trial
Patients with ssc-ild receiving double immunosuppression with or without anti fibrotic tratment
Eligibility criteria
Qualifiers
None
Disqualifiers
ssc without ild
Trial design
Treatments tested in this trial
- Antifibrotic drugs (nidanib or pirfenidone)
- MMF Immunosuppression
Treatment groups
35 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov